Objectives Goals of the 11-14 week scanGoals of the 11-14 week scan Fetal nuchal translucency in the detection of aneuploidyFetal nuchal translucency in.

Slides:



Advertisements
Similar presentations
NON – INVASIVE PRENATAL TESTING
Advertisements

SOUTH AUSTRALIAN MATERNAL SERUM ANTENATAL SCREENING (SAMSAS© ) PROGRAM
Antenatal Screening Dr Emma Parry CMFM
Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
INVERSION OF ANTENATAL PYRAMID
Prevention of Birth Defects An Overview of Primary and Secondary Strategies.
Second-trimester maternal serum screening
Fetal Testing During Pregnancy
Computational Intelligence
Genetics and Primary Care
Prenatal Testing for Down Syndrome: Where Do We Stand Today? David B. Fox, MD Riverside Methodist Hospital.
Prenatal Genetics OG Supplemental Information Drs. Deborah Driscoll and Michael Mennuti.
Antenatal Care DR. Yasir Katib MBBS, FRCSC Perinatologest.
NON – INVASIVE PRENATAL TESTING
Prenatal diagnosis Dr Neda Bogari.
Enhanced Prenatal Screening Program
Supachai Nathongchai, MD.
Biochemical tests and ‘marker chemicals’
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
The Early Gestation Scan. Embryonic/fetal growth 1 st trimester Crown rump lengthbest index of gestational lengthCrown rump lengthbest index of gestational.
Pregnancy & Newborn Screening Developments
Ultrasound imaging.
Ultrasound markers of chromosomal abnormalities
Photo: courtesy Travel Alberta.  The provision of information for individuals  Women have the right to access information about the health of their.
TEMPLATE DESIGN © Retrospective Analysis of Amniocentesis in UKMMC ZulidaR, MAJamil Universiti Putra Malaysia, UPM Serdang,
Fetal Assessment Fred Hill, MA, RRT. Ultrasound Ultrasound.
First Trimester Screening
Routine Anomaly Scan Ilse Erasmus.
Amirkabir imaging center dr.m.ali mohammadi 2011.
First and Early Second Trimester Diagnosis of Fetal Heart Disease 성균관의대 소아과 삼성제일병원 진단방사선과 민 지 연.
MULTIPLE PREGNANCY King Khalid University Hospital Department of Obstetrics & Gynecology Course 482.
Report of Iranian fetuses’s CRL at GA between 11W+0D to 13W+6D
產科常見檢查 R 4 蔡曉文. Screening for neural tube defects and Down syndrome Screening: identifies individuals whose risk is high for further evaluation. Screening:
National Women’s Screening for Aneuploidy Dr Emma Parry CMFM Clinical Director Maternal-Fetal Medicine National Women’s Health.
In the name of god First Trimester Screening Dr.M.Moradi.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
Epidemiological Monitoring and Quality Control of Nuchal Translucency Jack Canick Intensive Course on Screening for Down’s Syndrome Wolfson Institute of.
VI. Hrvatski kongres o ginekološkoj endokrinologiji, humanoj reprodukciji i menopavzi s međunarodnim sudjelovanjem , Brijuni DARIJA STRAH.
1 st Trimester AIUM/ACOG/ACR Guidelines  Transabdominal and/or transvaginal imaging  Appropriate labeling required  Uterus, including the cervix and.
In the name of god.
Vajiheh Marsoosi, M.D Associate Professor of TUMS Shariati Hospital.
The Role of Prenatal screening as part of Routine Obstetric Care
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the ability.
NHS Fetal Anomaly Screening Programme Marie Coughlin Screening Lead January 25 th 2010.
Fetal Period: SA Question 1 During the fetal period, the head growth is much slower than the rest of the body. A. True B. False 1.
Conceptual & technical advances in Down’s syndrome screening Howard Cuckle
Screening for Down’s syndrome
Nuchal Translucency (NT) Screen Ernest F. Talarico, Jr., Ph.D. Associate Director of Medical Education Associate Professor of Anatomy & Cell Biology Associate.
Erika Castro, PGY 3 Cook County-Loyola-Provident Family Medicine Residency 2/27/2014 PRENATAL SCREENING AND DIAGNOSIS COUNSELING
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
Fetal Diagnosis & Counseling of Pregnancy Options.
ZOO405 by Rania Baleela is licensed under a Creative Commons Attribution- NonCommercial-ShareAlike 3.0 Unported LicenseRania BaleelaCreative Commons Attribution-
UOG Journal Club: July 2013 Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies M. M. Gil, M. S. Quezada, B. Bregant,
Challenges of screening for fetal abnormalities
Current practice of cfDNA testing
UOG Journal Club: January 2016
بنام خدا.
Prenatal monitoring.
Antenatal Screening Rebecca Sykes.
Diagnostic amniocentesis AND Chorionic villus sampling
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
غربالگری ناهنجاریهای جنین
Objectives Goals of the week scan
Prenatal Screening for Genetic Conditions
guidance on antenatal screening
Ultrasound in fetal screening ( Down syndrome,…)
NON – INVASIVE PRENATAL TESTING
IN THE NAME OF GOD First trimester screening for aneuploidy
Nuchal translucency screening uses ultrasound to screen for Down syndrome, other conditions caused by an extra chromosome (trisomy 13 and 18), and congenital.
Presentation transcript:

Objectives Goals of the week scanGoals of the week scan Fetal nuchal translucency in the detection of aneuploidyFetal nuchal translucency in the detection of aneuploidy The value of first trimester maternal serum markers in the detection of aneuploidyThe value of first trimester maternal serum markers in the detection of aneuploidy Criteria for measurement of fetal nuchal translucencyCriteria for measurement of fetal nuchal translucency Pitfalls in the measurement of fetal nuchal translucencyPitfalls in the measurement of fetal nuchal translucency The significance of an increased nuchal translucency with a normal karyotypeThe significance of an increased nuchal translucency with a normal karyotype Management of an increased nuchal translucencyManagement of an increased nuchal translucency Quality control of a nuchal translucency screening programQuality control of a nuchal translucency screening program Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004 Edchen99 提供

The goals of the weeks scan Screening for trisomy 21 and other major chromosomal defectsScreening for trisomy 21 and other major chromosomal defects Early diagnosis of major abnormalities, e.g. anencephaly, exomphalosEarly diagnosis of major abnormalities, e.g. anencephaly, exomphalos Diagnosis of twins in about 2% of pregnancies & determination of chorionicityDiagnosis of twins in about 2% of pregnancies & determination of chorionicity Diagnosis of missed miscarriage in about 3% of pregnanciesDiagnosis of missed miscarriage in about 3% of pregnancies Early and accurate dating of pregnancyEarly and accurate dating of pregnancy Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

In normal pregnancies, fetal NT thickness increases with gestation In normal pregnancies, fetal NT thickness increases with gestation In trisomy 21 pregnancies fetal NT is increased (above the 95 th centile in about 75% of cases) In trisomy 21 pregnancies fetal NT is increased (above the 95 th centile in about 75% of cases) Nuchal translucency as a function of crown-rump length (gestational age) Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004 Trisomy 21

The risk for trisomy 21 is derived by multiplying the a priori maternal age and gestation-related risk by a likelihood ratio (LR)The risk for trisomy 21 is derived by multiplying the a priori maternal age and gestation-related risk by a likelihood ratio (LR) The LR depends on the degree of deviation in fetal NT from the expected normal median for that crown–rump length. The LR depends on the degree of deviation in fetal NT from the expected normal median for that crown–rump length. Screening for trisomy 21 Assessment of risk by maternal age and fetal nuchal translucency Risk (%) Maternal age A priori risk NT NT Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

PAPP-A (SD) % Normal PAPP-A Free ßhCG (SD) % Normal Free  hCG Trisomy 21 Risk assessment with maternal serum free ß-hCG & PAPP-A Trisomy 21 Alterations in maternal serum biochemistry are independent of fetal NT thicknessAlterations in maternal serum biochemistry are independent of fetal NT thickness Screening for trisomy 21 by a combination of fetal NT and maternal serum free ß-hCG and PAPP-A can identify about 90% of affected fetuses for a false positive rate of 5%.Screening for trisomy 21 by a combination of fetal NT and maternal serum free ß-hCG and PAPP-A can identify about 90% of affected fetuses for a false positive rate of 5%. Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

100,000 pregnancies Maternal age 60 30% Serum biochemistry at 16 wks % Nuchal translucency (NT) at 12 wks 75% 150 Fetal NT & ß-hCG & PAPP- A at 12 wks % Screening for trisomy 21 Effectiveness of different methods of screening Method of screening Number detected Detection rate Screen positive 5% N=5,000 Trisomy 21 N=200 Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Maternal serum biochemistry and ultrasound parameters in the detection of chromosomal abnormalities other than trisomy 21 Fetal heart rate Crown-rump length Increased NT Ultrasound markers Free ß-hCG PAPP-A Trisomy 18 75% Exomphalos Single umbilical artery  X0 (Turner) 87% Trisomy 13 72% MegacystisHoloprosencephaly  Triploidy59% Small / molar placenta  / / / /  / / / / Screening for trisomy 21 by a combination of fetal nuchal translucency and maternal serum free ß-hCG and PAPP-A can also identify about 90% of fetuses with other major chromosomal defectsScreening for trisomy 21 by a combination of fetal nuchal translucency and maternal serum free ß-hCG and PAPP-A can also identify about 90% of fetuses with other major chromosomal defects Each of these chromosomal defects is associated with its own syndromal pattern of sonographic and biochemical markersEach of these chromosomal defects is associated with its own syndromal pattern of sonographic and biochemical markers Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Frequency of death and/or major anomaly in fetuses with an increased nuchal translucency and a normal karyotype Death or major anomaly 69% > 6.5 mm 14% NT 3% % % Souka et al. Ultrasound Obstet Gynecol 2001;18:9-17; n=1,320 Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

AchondrogenesisAchondroplasia Asphyxiating thoracic dystrophy Blomstrand osteochondrodysplasia Campomelic dysplasia Hypophosphatasia Jarcho-Levin syndrome Nance-Sweeney syndrome Osteogenesis imperfecta Roberts syndrome Short-rib-polydactily syndrome Sirenomelia Thanatophoric dysplasia CraniosynostosisIniencephalyAgnathia/micrognathia Cardiac defects Diaphragmatic hernia ExomphalosMegacystis Renal agenesis Polycystic kidneys Multicystic kidneys Nephrotic syndrome Body stalk anomaly Congenital lymphedema Akinesia deformation sequence Myotonic dystrophy Spinal muscular atrophy Beckwith-Wiedemman syndrome GM1-gangliosidosis Mucopolysaccharidosis type VII Smith-Lemli-Opitz syndrome Vitamin D resistant rickets Zellweger syndrome Blackfan Diamond anaemia Dyserythropoietic anaemia Thalassaemia-  Parvovirus B19 infection Brachmann-de Lange syndrome Charge association di George syndrome EEC syndrome Fryn syndrome Noonan syndrome Perlman syndrome Stickler syndrome Treacher-Collins syndrome Trigonocephaly C syndrome VACTER association Conditions associated with increased nuchal translucency and normal karyotype Souka et al. Ultrasound Obstet Gynecol 2001;18:9-17 Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

11-14 weeks Fetal karyotyping Anomaly scan Chromosomal defects Major abnormalities Normal karyotype No abnormalities weeks Anomaly scan Echocardiography No abnormalities Resolving nuchal Major abnormalities No abnormalities Persistent nuchal TORCH & Parvovirus screen Genetic testing 20 weeks Anomaly scan Echocardiography No abnormalities Major abnormalities No abnormalities Persistent nuchal TORCH & Parvovirus screen Genetic testing Proposed management of increased nuchal translucency Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

 Dichorionic 80%  Monochorionic 20% Diagnosis of monochorionic or dichorionic twins Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Frequency of complications as a function of chorionicity in twin gestations 2%12% Miscarriage (11-23 weeks) 1.5%3% Perinatal death (>23 weeks) 10%20% Fetal growth restriction 5%10% Preterm delivery (<32 weeks) DichorionicMonochorionic Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Twins gestation Determine chorionicityDetermine chorionicity Measure nuchal translucency (NT) in each fetusMeasure nuchal translucency (NT) in each fetus Calculate the combined maternal age and fetal NT risk for each fetusCalculate the combined maternal age and fetal NT risk for each fetus The risk can be adjusted by multiplying with the likelihood ratio derived from maternal serum free ß-hCG and PAPP-AThe risk can be adjusted by multiplying with the likelihood ratio derived from maternal serum free ß-hCG and PAPP-A Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Twin gestation: counselling Dichorionic twins Counsel the parents on the risks of having one or two affected fetuses Counsel the parents on the risks of having one or two affected fetuses If parents choose invasive testing the preferred option is chorionic villous sampling, because if one fetus is affected and the parents want selective fetocide the risk of miscarriage is considerably lower if fetocide is performed in the first rather than the second trimester If parents choose invasive testing the preferred option is chorionic villous sampling, because if one fetus is affected and the parents want selective fetocide the risk of miscarriage is considerably lower if fetocide is performed in the first rather than the second trimester Monochorionic twins Counsel the parents that the risk of both fetuses being affected is the average one derived from that calculated for each fetus Counsel the parents that the risk of both fetuses being affected is the average one derived from that calculated for each fetus If parents choose invasive testing the preferred option is chorionic villous sampling, because if the fetuses are affected the parents can have early termination If parents choose invasive testing the preferred option is chorionic villous sampling, because if the fetuses are affected the parents can have early termination If there is a large discordancy in NT between the two fetuses consider the diagnosis of twin-to-twin transfusion syndrome If there is a large discordancy in NT between the two fetuses consider the diagnosis of twin-to-twin transfusion syndrome Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Theoretical course & examination Theoretical course & examination Practical training Practical training Logbook of 10 images Logbook of 10 images Install software for risk assessment Yearly audit Yearly audit Distribution of NTs Distribution of NTs Quality of 5 images Quality of 5 images Training and quality assurance in the weeks scan by the Fetal Medicine Foundation Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Principles of screening, pre-test and post-test counselling. Principles of screening, pre-test and post-test counselling. Amniocentesis and chorionic villus sampling. Fetal cells and free DNA in maternal blood. Amniocentesis and chorionic villus sampling. Fetal cells and free DNA in maternal blood. FMF guidelines on the measurement of NT. FMF guidelines on the measurement of NT. Screening for chromosomal defects by fetal NT and maternal serum biochemistry. Screening for chromosomal defects by fetal NT and maternal serum biochemistry. Management of pregnancies with increased NT after the diagnosis of normal karyotype. Management of pregnancies with increased NT after the diagnosis of normal karyotype. Diagnosis and management of major fetal defects, such as anencephaly & exomphalos Diagnosis and management of major fetal defects, such as anencephaly & exomphalos These are found in about 1% of pregnancies Diagnosis of multiple pregnancies, determination of chorionicity and management. Diagnosis of multiple pregnancies, determination of chorionicity and management. These are found in about 2% of pregnancies. Diagnosis and management of missed miscarriage detected at the weeks scan Diagnosis and management of missed miscarriage detected at the weeks scan This is found in about 3% of pregnancies. Theoretical course: content Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Gestation wks Gestation wks Crown-rump length mm Crown-rump length mm Mid-sagittal view Mid-sagittal view Image size: head and thorax Image size: head and thorax Neutral position Neutral position Away from amnion Away from amnion Maximum lucency Maximum lucency Callipers on-to-on Callipers on-to-on Criteria for proper measurement of nuchal translucency Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

The image should have the head and thorax only Each movement of the calliper gives a 0.1 mm change of the measurement Measurement of nuchal translucency The importance of image magnification Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Hyperextended Measurement of nuchal translucency Head position Hyperextended head may falsely increase NT measurement Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Measurement of nuchal translucency Mid-sagittal section Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Measurement of nuchal translucency: calliper placement Underestimate Overestimate Correct(inner-to-inner) Correct placement of the callipers to assess nuchal translucency based upon published nomograms by the Fetal Medicine Foundation Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

CRL: 54 mm Risk (%) Age (years) : 600 1: 3, : The correct measurement is 2.9 Measurement of nuchal translucency Use the longest measurement Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

A nuchal cord is found in 5% of cases Measure the NT above and below the umbilical cord and use the average measurement for calculation of risk Measurement of nuchal translucency in the presence of a nuchal cord Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Criteria to obtain and maintain certification Submit 10 images for review by quality control center True sagittal section True sagittal section Image size: head & thorax Image size: head & thorax Neutral position Neutral position Callipers on-to-on Callipers on-to-on Maximum lucency Maximum lucency Criteria for evaluating the images by the quality control center (Fetal Medicine Foundation) Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

1. PASS: All 5 criteria fulfilled in at least 8 of the 10 images unsatisfactory images: Submit another 5 images unsatisfactory images: Submit another 10 images Evaluation of the images and action Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Crown- rump length (mm) Nuchal translucency (mm) 40-60% of measurements above the median ACTION: Renew license of the software for 1 year Audit of distribution of nuchal translucency measurements for renewal of certification Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

Under-estimating Crown- rump length (mm) Nuchal translucency (mm) >60% of measurements below the median ACTION: Renew license of the software for 3 months only and reassess Crown- rump length (mm) Nuchal translucency (mm) Over-estimating >60% of measurements above the median Audit of distribution of nuchal translucency measurements for renewal of certification Nicolaides KH. Fetal nuchal translucency. Am J Obstet Gynecol 2004

For more images and information of the weeks scan, the reader is referred to The Week Scan The Diagnosis of Fetal Abnormalities at the following website: The material is freely available for review